"We are also announcing that whether or not this petition is approved, our nationwide network of attorneys will continue to offer free legal consultations to consumers seeking information about legal options they may have to seek compensation for their allegations involving pancreatic or thyroid cancer," said Resource4thePeople.
The U.S. Food and Drug Administration issued a March 14, 2013 announcement** about its investigation into possible links between these medications and pancreatitis and cancer.
The FDA identified these drugs as exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto).
The complimentary consultations were offered in response to a large volume of inquiries from consumers triggered by the FDA's announcement about possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs.
“There are a significant number of Americans who treat their diabetes with these medications and the FDA announcement has had widespread ramifications in terms of patients seeking information about their legal options,” said Resource4thePeople.
“In its announcement, an FDA spokesman said that the findings were based on examination of a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes."
The FDA has asked researchers to provide the methodology used to collect and study these specimens and to provide the tissue samples so the agency can further investigate potential pancreatic toxicity associated with the incretin mimetics.
Byetta was originally approved by the FDA and released onto the market in 2005, with its primary function being to help patients with di
Copyright©2012 Vocus, Inc.
All rights reserved